APA (7th ed.) Citation

D, O., R, S., S, G., Y, N., M, N., S, I., . . . H, K. (2025). Efficacy and safety of bispecific antibodies in multiple myeloma patients with end-stage renal disease undergoing hemodialysis: A case report of elranatamab and a literature review. Annals of hematology, 104(11), 6075. https://doi.org/10.1007/s00277-025-06689-0

Chicago Style (17th ed.) Citation

D, Ogiya, et al. "Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma Patients with End-stage Renal Disease Undergoing Hemodialysis: A Case Report of Elranatamab and a Literature Review." Annals of Hematology 104, no. 11 (2025): 6075. https://doi.org/10.1007/s00277-025-06689-0.

MLA (9th ed.) Citation

D, Ogiya, et al. "Efficacy and Safety of Bispecific Antibodies in Multiple Myeloma Patients with End-stage Renal Disease Undergoing Hemodialysis: A Case Report of Elranatamab and a Literature Review." Annals of Hematology, vol. 104, no. 11, 2025, p. 6075, https://doi.org/10.1007/s00277-025-06689-0.